WASHINGTON (dpa-AFX) - Myriad Genetics, Inc. (MYGN) has submitted a supplementary application with the Japanese Ministry of Health Labour and Welfare for its BRACAnalysis Diagnostic System to be used as a companion diagnostic to help to identify people with metastatic pancreatic or metastatic castration-resistant prostate cancer who have germline BRCA1 and BRCA2 mutations.
The company's BRACAnalysis Diagnostic System previously was approved in Japan to identify patients with ovarian or breast cancer who have a germline BRCA mutation and are eligible for Lynparza therapy.
Copyright RTT News/dpa-AFX
© 2020 AFX News
